This article was accepted into the corpus but its outbound wikilinks were never NER-processed — typical at the deepest BFS hop or when the run's entity cap was reached. No expansion funnel to show.
| zidovudine | |
|---|---|
| Name | Zidovudine |
| Tradename | Retrovir |
| Synonyms | AZT, azidothymidine |
| Routes of administration | Oral, intravenous |
| Class | Nucleoside analogue reverse transcriptase inhibitor |
| Metabolism | Hepatic glucuronidation |
| Elimination half-life | 0.5–3 hours |
| Legal status | Rx-only |
zidovudine is an antiretroviral medication used in the treatment and prevention of infections caused by human immunodeficiency virus. It was the first approved therapy shown to reduce viral replication and improve outcomes in people with HIV infection and has been used in combination regimens to reduce mother-to-child transmission. Clinical deployment transformed responses to the AIDS epidemic and influenced policies at institutions such as the World Health Organization, Centers for Disease Control and Prevention, and national health agencies.
Zidovudine is indicated for treatment of HIV-1 infection in combination with other antiretroviral agents and for perinatal prophylaxis to prevent vertical transmission during labor and delivery, adopted by programs in United Kingdom, United States, South Africa, and other national health systems. It has been used in post-exposure prophylaxis after occupational exposures among staff in World Health Organization guidelines and in non-occupational exposure protocols endorsed by agencies including the Centers for Disease Control and Prevention, European Centre for Disease Prevention and Control, and national ministries of health. In some settings zidovudine is incorporated into combination antiretroviral therapy regimens alongside agents from classes developed by companies such as Gilead Sciences, Merck & Co., and GlaxoSmithKline and recommended in treatment guidelines from bodies like the International AIDS Society.
Zidovudine is a thymidine analogue that, after intracellular phosphorylation by host kinases, competes with endogenous nucleotides for incorporation into viral DNA synthesized by HIV reverse transcriptase, a mechanism shared with other nucleoside reverse transcriptase inhibitors used in regimens informed by research at institutions such as National Institutes of Health and Pasteur Institute. Incorporation of the analogue terminates DNA chain elongation and thus inhibits reverse transcription of the viral RNA genome, reducing viremia observable in clinical trials conducted at centers like Harvard Medical School, Johns Hopkins University, and University of Cape Town. Its action specifically targets HIV-1 and HIV-2 reverse transcriptase enzymes studied in biochemical work associated with laboratories at Max Planck Society and Cold Spring Harbor Laboratory.
After oral administration zidovudine is well absorbed with bioavailability influenced by first-pass hepatic metabolism mediated by enzymes characterized in studies from University of California, San Francisco and University of Oxford. The compound undergoes glucuronidation in the liver and elimination via renal excretion; half-life estimates have been reported in pharmacokinetic studies from Mayo Clinic and Cleveland Clinic populations. Drug interactions have been documented with agents including those developed by Pfizer, AbbVie, and Roche and assessed in trials overseen by regulatory authorities such as the U.S. Food and Drug Administration and European Medicines Agency. Dosing adjustments may be necessary in individuals with renal or hepatic impairment following guidance used in practice at hospitals like Karolinska University Hospital and Mount Sinai Hospital.
Common adverse effects observed in randomized trials at institutions such as Vanderbilt University and Columbia University include anemia, neutropenia, headaches, and gastrointestinal symptoms; these hematologic toxicities have required monitoring protocols adapted by clinical programs at Royal Free Hospital and Groote Schuur Hospital. Long-term toxicities reported in cohort studies from University College London and Stanford University include myopathy and lactic acidosis associated with mitochondrial dysfunction, findings that influenced surveillance recommendations by the World Health Organization and national bodies. Hypersensitivity reactions and drug interactions reported in pharmacovigilance databases maintained by the U.S. Food and Drug Administration and European Medicines Agency also informed labeling changes and risk mitigation strategies.
Resistance to zidovudine develops via mutations in the reverse transcriptase gene of HIV described in molecular epidemiology studies at Institut Pasteur and Los Alamos National Laboratory. Primary mutations such as those analyzed in work affiliated with Fred Hutchinson Cancer Research Center and Sanger Institute reduce susceptibility and can confer cross-resistance with other nucleoside analogues, shaping combination therapy approaches adopted by the International Antiviral Society–USA and national treatment panels. Surveillance of resistance-associated mutations has been integrated into public health programs run by organizations such as UNAIDS and the European Centre for Disease Prevention and Control.
Zidovudine was first synthesized and investigated in antiviral screens at research centers including laboratories tied to the United States Public Health Service and later advanced through clinical trials at academic sites such as New York University and University of North Carolina. Regulatory approval by the U.S. Food and Drug Administration followed landmark clinical trials that demonstrated reductions in opportunistic infections and mortality among people with AIDS, precipitating rapid incorporation into national treatment recommendations from agencies like the National Institutes of Health and reshaping responses to the AIDS epidemic. Patenting, manufacturing, and global distribution involved pharmaceutical companies and programs coordinated with international organizations including World Health Organization and Médecins Sans Frontières to expand access in low-income settings.
The introduction of zidovudine had broad social and cultural impacts across advocacy movements such as ACT UP and policy debates in legislative bodies like the United States Congress and parliaments in South Africa and United Kingdom. Issues of access, pricing, and ethics engaged institutions such as Human Rights Watch and Amnesty International and provoked litigation and policy reforms concerning pricing strategies of pharmaceutical firms like Burroughs Wellcome and later corporate successors. Public health campaigns in regions affected by the epidemic referenced guidance from World Health Organization, UNAIDS, and national ministries, contributing to evolving norms in prevention, treatment, and human rights discourse.
Category:Antiretroviral drugs